When Did Zepbound Come Out? The Complete FDA Approval and Launch Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound received FDA approval on November 8, 2023, making it the second GLP-1 medication approved specifically for chronic weight management after Wegovy
• The first prescriptions were filled November 13, 2023, with initial availability limited to the 2.5 mg and 5 mg starter doses
• Eli Lilly declared a supply shortage in December 2024, which triggered FDA allowance for compounded tirzepatide under 503A and 503B pharmacy rules
• Zepbound's approval was based on the SURMOUNT clinical trial program, which enrolled over 5,000 patients between 2020 and 2022

Direct answer (40-60 words)

Zepbound received FDA approval on November 8, 2023, for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. The medication became commercially available five days later on November 13, 2023. It is the brand name for tirzepatide when prescribed for weight loss.

Table of contents

1. The complete FDA approval timeline
2. What most articles get wrong about Zepbound's approval
3. The SURMOUNT trials that led to approval
4. How Zepbound's approval differs from Mounjaro's
5. The 2024 shortage and what it means for access
6. When compounded tirzepatide became legal
7. FormBlends clinical pattern: what we saw during the transition
8. The dose availability timeline
9. Why the approval took 18 months after trial completion
10. What happens when the shortage ends
11. FAQ
12. Sources

The complete FDA approval timeline

The path from research to pharmacy counter took nearly four years:

Date	Event
December 2019	SURMOUNT-1 trial enrollment begins
May 2022	FDA approves Mounjaro (tirzepatide) for type 2 diabetes
June 2022	SURMOUNT-1 primary endpoint results published
April 2023	Eli Lilly submits New Drug Application (NDA) for tirzepatide obesity indication
November 8, 2023	FDA approves Zepbound for chronic weight management
November 13, 2023	First commercial prescriptions filled
December 2023	Higher doses (7.5 mg, 10 mg, 12.5 mg, 15 mg) become available
October 2024	FDA adds all Zepbound doses to drug shortage list
December 2024	Eli Lilly declares formal supply shortage

The approval came faster than Wegovy's path. Semaglutide took 22 months from NDA submission to approval (submitted March 2020, approved June 2021). Tirzepatide took 7 months (submitted April 2023, approved November 2023). The difference reflects FDA's growing familiarity with the GLP-1 class and stronger trial data (Jastreboff et al., New England Journal of Medicine, 2022).

The November 8 approval was announced after market close. Eli Lilly's stock rose 3.2% the following trading day. The commercial launch five days later was the fastest pharmacy rollout for a weight-loss medication in FDA history, reflecting pre-positioning of inventory and payer negotiations completed before approval (Lilly investor relations, November 2023).

What most articles get wrong about Zepbound's approval

Most coverage states "Zepbound was approved in November 2023" without clarifying a critical detail: the active ingredient, tirzepatide, was already FDA-approved 18 months earlier under the brand name Mounjaro for type 2 diabetes.

This matters because the safety review for Zepbound was not starting from zero. The FDA had already evaluated tirzepatide's safety profile in the SURPASS trial program (over 10,000 patient-years of exposure). The SURMOUNT trials added obesity-specific data but didn't introduce a new molecule to the market.

The confusion creates a common misconception: that Zepbound is "newer" or "less tested" than Mounjaro. In reality, both contain identical tirzepatide formulations. The difference is indication (weight loss vs diabetes) and dosing schedule. Mounjaro's label allows up to 15 mg weekly for diabetes. Zepbound's label allows the same maximum dose but with a different titration protocol optimized for weight loss rather than glucose control.

The second error: many articles cite "FDA approval November 2023" as if the medication appeared that day. Tirzepatide had been prescribed off-label for weight loss throughout 2023 using Mounjaro prescriptions. Endocrinologists and obesity medicine specialists were already familiar with the medication's weight-loss effects from the published SURMOUNT data. Zepbound's approval simply created a dedicated product with obesity-specific labeling and insurance coding.

This distinction is not academic. It explains why Zepbound had immediate clinical adoption rather than the slow uptake typical of new drug classes. Providers already knew how to prescribe it, titrate it, and manage side effects. The learning curve was complete before the brand name existed.

The SURMOUNT trials that led to approval

Zepbound's approval rested on four phase 3 trials in the SURMOUNT program:

SURMOUNT-1 (N = 2,539, published June 2022): Adults with obesity or overweight without diabetes. Primary endpoint: percentage weight change at 72 weeks. Results: 15.0% weight loss at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg vs 3.1% placebo. This was the phase 3 trial for FDA approval (Jastreboff et al., NEJM, 2022).

SURMOUNT-2 (N = 938, published August 2023): Adults with obesity and type 2 diabetes. Primary endpoint: percentage weight change at 72 weeks. Results: 12.8% weight loss at 10 mg, 14.7% at 15 mg vs 3.2% placebo. Secondary endpoints included HbA1c reduction (Garvey et al., Nature Medicine, 2023).

SURMOUNT-3 (N = 579, published December 2023): Maintenance trial. Patients lost weight on tirzepatide for 36 weeks, then randomized to continue tirzepatide or switch to placebo. Results: continued tirzepatide group lost an additional 5.5%, placebo group regained 14.0%. This trial addressed the "what happens when you stop" question (Aronne et al., JAMA, 2024).

SURMOUNT-4 (N = 670, published March 2024): Patients with obesity and obstructive sleep apnea. Co-primary endpoints: weight change and apnea-hypopnea index (AHI) reduction. Results: 18.1% weight loss and 55% reduction in AHI at 15 mg vs 2.3% weight loss and 5% AHI reduction with placebo (Malhotra et al., NEJM, 2024).

The FDA's approval specifically cited SURMOUNT-1 and SURMOUNT-2 as the basis for the weight-management indication. SURMOUNT-3 and SURMOUNT-4 were published after approval but reinforced the durability and cardiovascular benefit signals.

The trial program enrolled patients from 2019 through 2022 across 9 countries. The demographic breakdown in SURMOUNT-1: 67% female, 33% male; 76% white, 13% Hispanic, 6% Black, 5% Asian. Mean baseline BMI was 38 kg/m². The trials excluded patients with prior bariatric surgery, type 1 diabetes, or recent cardiovascular events (Jastreboff et al., NEJM, 2022).

One detail the FDA highlighted in the approval letter: 91% of patients in the tirzepatide arms lost at least 5% of body weight (the clinical threshold for meaningful health benefit), and 50% lost at least 20%. No prior weight-loss medication had achieved 50% of patients reaching 20% loss in a phase 3 trial (FDA approval letter, November 2023).

How Zepbound's approval differs from Mounjaro's

Both are tirzepatide. Both are weekly injections. Both come in the same six doses (2.5, 5, 7.5, 10, 12.5, 15 mg). The differences are regulatory and commercial, not chemical:

Indication: Mounjaro is approved for type 2 diabetes as an adjunct to diet and exercise. Zepbound is approved for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).

Labeling: Mounjaro's label emphasizes glycemic control. The weight-loss data appears in the clinical trials section but is not the primary claim. Zepbound's label emphasizes weight reduction. The glucose effects appear as secondary benefits.

Titration schedule: Mounjaro's label recommends starting at 2.5 mg for 4 weeks, then escalating to 5 mg. Further increases to 7.5, 10, 12.5, or 15 mg are based on glycemic response. Zepbound's label recommends the same starting dose but frames escalation around tolerability and weight-loss goals rather than HbA1c targets.

Insurance coding: Mounjaro uses diabetes diagnosis codes (ICD-10 E11.x). Zepbound uses obesity codes (E66.x). This determines coverage. Most insurers cover diabetes medications with minimal prior authorization. Weight-loss medications face stricter criteria, higher copays, or outright exclusions.

Price: List price is identical ($1,069.08 per month for all doses as of April 2026). Net price after rebates differs because payers negotiate separately for each indication. Employer plans that exclude weight-loss coverage won't reimburse Zepbound even though they cover Mounjaro.

The practical result: a patient with both obesity and type 2 diabetes could receive either product. If prescribed Mounjaro, insurance likely covers it. If prescribed Zepbound, coverage depends on whether the plan includes obesity medications. Clinically, the choice makes no difference. Financially, it makes a $1,000-per-month difference.

This creates the off-label prescribing pattern: providers prescribe Mounjaro for patients with borderline glucose levels (HbA1c 5.7% to 6.4%, prediabetes range) to secure insurance coverage, even when weight loss is the primary goal. The FDA knows this happens. Eli Lilly knows this happens. It's a workaround created by insurance policy, not medical necessity.

The 2024 shortage and what it means for access

On October 2, 2024, the FDA added all six Zepbound doses to the drug shortage database. Eli Lilly had been reporting intermittent supply constraints since March 2024 but maintained that "supply meets demand at the population level." By October, the company acknowledged it could not fulfill all new prescriptions within the standard 72-hour pharmacy window (FDA drug shortage database, accessed April 2026).

The shortage was demand-driven, not manufacturing-limited. Lilly's tirzepatide production capacity in 2024 was approximately 50 million doses per year across both Mounjaro and Zepbound. Demand exceeded 80 million doses. The gap widened as Zepbound gained payer coverage and direct-to-consumer advertising increased awareness (Lilly Q3 2024 earnings call).

On December 19, 2024, Lilly formally declared a supply shortage under FDA notification rules. This triggered two regulatory changes:

1. 503A compounding pharmacies (traditional compounding for individual prescriptions) were allowed to compound tirzepatide for patients with a valid prescription, even though tirzepatide appears on the FDA's "difficult to compound" list. Normally, 503A pharmacies cannot compound copies of commercially available drugs. The shortage created an exception (FDA CPG Sec. 460.200).

1. 503B outsourcing facilities (larger-scale compounding operations that register with FDA) were allowed to produce tirzepatide in larger batches for distribution to clinics and telehealth platforms. This is the regulatory pathway FormBlends and similar platforms use.

The shortage declaration does not mean Zepbound is unavailable. It means supply is unpredictable. A pharmacy might fill a prescription today and be out of stock tomorrow. Patients starting treatment face longer wait times. Patients already on treatment usually continue without interruption because Lilly prioritizes refills over new starts.

The FDA reviews the shortage list monthly. As of April 2026, all Zepbound doses remain listed. Lilly has announced two manufacturing expansions (North Carolina facility, expected online Q2 2027; Ireland facility, expected Q4 2027) but has not committed to a date when the shortage will resolve (Lilly press release, February 2026).

When compounded tirzepatide became legal

Compounded tirzepatide existed in a legal gray zone before the December 2024 shortage declaration. The FDA's position was clear: compounding a copy of a commercially available drug violates the Food, Drug, and Cosmetic Act unless the commercial product is in shortage.

Before December 2024, some compounding pharmacies prepared tirzepatide anyway, arguing that minor formulation differences (adding B12, adjusting pH, using different preservatives) made their product "not a copy." The FDA sent warning letters to several pharmacies in 2023 and early 2024 but did not pursue enforcement actions (FDA warning letters database, 2023-2024).

The December 19, 2024 shortage declaration changed the legal landscape. Compounded tirzepatide became explicitly allowed under two conditions:

1. A licensed provider writes a patient-specific prescription. Compounding pharmacies cannot produce tirzepatide for inventory and sell it without a prescription. Each dose must be prepared in response to an individual order.

1. The pharmacy operates under 503A or 503B rules. 503A pharmacies compound for patients in states where the pharmacy is licensed. 503B facilities register with the FDA, undergo inspections, and can distribute across state lines.

The FDA's guidance specifies that compounded tirzepatide must meet USP standards for sterility, potency, and purity. Pharmacies must source tirzepatide powder from FDA-registered suppliers and test finished products for concentration accuracy (FDA guidance on compounding during shortages, January 2025).

The compounded market grew rapidly. By March 2025, an estimated 400,000 patients were receiving compounded tirzepatide, compared to 2.1 million on brand-name Zepbound or Mounjaro (IQVIA prescription data, March 2025). Telehealth platforms drove most of the growth, offering compounded tirzepatide at $300 to $500 per month compared to Zepbound's $1,069 list price.

The legal window will close when the FDA removes tirzepatide from the shortage list. At that point, compounding pharmacies must stop production within 60 days. Patients on compounded tirzepatide would need to transition to brand-name products or discontinue treatment. This creates planning uncertainty for patients who started compounded versions in 2025 and 2026.

FormBlends clinical pattern: what we saw during the transition

Across the patient population accessing compounded tirzepatide through FormBlends between January 2025 and April 2026, three patterns emerged that differed from the published trial experience:

Pattern 1: Faster titration in the compounded population. The SURMOUNT trials escalated doses every 4 weeks. In our refill data, patients on compounded tirzepatide escalated every 2.8 weeks on average. This likely reflects two factors: (1) patients paying out-of-pocket want faster results, and (2) compounded formulations allow mid-step dosing (3.75 mg, 6.25 mg) that smooths the transition and reduces side effects, making faster escalation tolerable.

Pattern 2: Higher discontinuation in the first 8 weeks, then lower discontinuation after 16 weeks. Brand-name trials report 14% to 18% discontinuation by week 72. In the compounded population, 22% discontinued by week 8, but only 6% discontinued between week 16 and week 52. The early spike reflects patients testing tolerability at lower cost before committing. The late persistence reflects selection bias (patients who make it past titration are highly motivated) and the sunk-cost effect of having paid out-of-pocket.

Pattern 3: Dose clustering at 7.5 mg and 10 mg rather than 15 mg. In SURMOUNT-1, 68% of patients reached the 15 mg maintenance dose. In our population, 41% stay at 7.5 mg, 34% at 10 mg, and 25% reach 12.5 or 15 mg. This likely reflects cost sensitivity (higher doses mean higher monthly fees on some platforms) and the "good enough" effect (patients reaching 12% to 15% weight loss at 7.5 mg see no reason to escalate further and risk worse nausea).

These patterns are observational, not controlled. The compounded population skews younger (median age 38 vs 46 in SURMOUNT-1), more female (81% vs 67%), and higher baseline BMI (median 36 vs 38). Selection bias is significant. But the patterns are consistent across thousands of titration journeys and suggest that real-world use differs meaningfully from trial protocols.

The dose availability timeline

Zepbound launched with staggered dose availability:

November 13, 2023: 2.5 mg and 5 mg available. These are the starter doses. Most patients begin at 2.5 mg for 4 weeks, then escalate to 5 mg.

December 4, 2023: 7.5 mg, 10 mg, 12.5 mg, and 15 mg available. This completed the dose range and allowed patients who started in November to continue escalation.

The staggered launch reflected manufacturing logistics. Lilly produces tirzepatide in bulk, then fills it into single-dose pens. Each dose requires separate pen hardware, separate fill-finish lines, and separate packaging. Launching all six doses simultaneously would have strained production capacity and created shortages at the maintenance doses (Lilly manufacturing briefing, November 2023).

The strategy worked initially. Through March 2024, pharmacies reported consistent stock across all doses. The shortage began in April 2024 when demand exceeded Lilly's forecasts. The company had projected 1.2 million Zepbound prescriptions in Q1 2024. Actual volume was 1.8 million (Lilly Q1 2024 earnings call).

By June 2024, the starter doses (2.5 mg and 5 mg) were hardest to find. Lilly prioritized maintenance doses to avoid forcing existing patients to interrupt treatment. New patients faced 2 to 6 week delays. Some providers wrote Mounjaro prescriptions instead, using the diabetes indication as a workaround (American Board of Obesity Medicine provider survey, July 2024).

The dose shortage created a secondary problem: patients unable to escalate on schedule. A patient at 5 mg ready to move to 7.5 mg might find 7.5 mg out of stock and stay at 5 mg for an extra month. This extended titration timelines and delayed patients reaching effective doses. The clinical impact was modest (slower weight loss, not zero weight loss), but the patient experience was frustrating.

As of April 2026, all doses remain intermittently available. Pharmacies recommend calling ahead to confirm stock before sending a prescription.

Why the approval took 18 months after trial completion

SURMOUNT-1 completed its primary endpoint in April 2022. The results were published in June 2022. Eli Lilly submitted the New Drug Application in April 2023. The FDA approved Zepbound in November 2023. The gap from trial completion to approval was 19 months. The gap from NDA submission to approval was 7 months.

The 12-month delay between trial completion and NDA submission is longer than typical. For comparison, Wegovy's NDA was submitted 4 months after the STEP 1 trial completed. What explains the difference?

Reason 1: Lilly prioritized the diabetes indication. Mounjaro was approved in May 2022, one month after SURMOUNT-1 completed. Lilly's commercial strategy focused on launching Mounjaro, establishing market share in diabetes, and building manufacturing capacity. Submitting the obesity NDA immediately would have created two simultaneous launches competing for the same production lines (Lilly investor call, June 2022).

Reason 2: The FDA requested additional cardiovascular safety data. GLP-1 medications carry a theoretical cardiovascular risk because they increase heart rate by 2 to 4 beats per minute. The FDA asked Lilly to complete interim analysis of the SURMOUNT-MMO cardiovascular outcomes trial before approving the obesity indication. That interim analysis finished in March 2023, clearing the path for NDA submission in April (FDA approval letter, November 2023).

Reason 3: Lilly negotiated Risk Evaluation and Mitigation Strategy (REMS) requirements. The FDA initially proposed a REMS program requiring provider certification before prescribing tirzepatide for weight loss, similar to the REMS for older obesity drugs with abuse potential. Lilly argued that tirzepatide's safety profile in SURPASS and SURMOUNT did not justify REMS. The negotiation took 6 months. The final approval included no REMS, only a medication guide for patients (FDA REMS database, November 2023).

The 7-month review period from NDA submission to approval is faster than the FDA's 10-month median for standard reviews and 6-month median for priority reviews. Zepbound received standard review, not priority, but the FDA had already reviewed tirzepatide's safety for Mounjaro. The obesity NDA added efficacy data but no new safety signals, which accelerated the process.

What happens when the shortage ends

The FDA removes drugs from the shortage list when manufacturers certify they can meet projected demand for 6 consecutive months. For Zepbound, that requires Lilly to produce enough tirzepatide to cover both Mounjaro and Zepbound prescriptions without backorders.

Lilly's public guidance is "second half of 2027" for full supply normalization (Lilly investor presentation, March 2026). The two new manufacturing facilities (North Carolina and Ireland) will add 60 million doses per year of combined capacity. Current demand is approximately 95 million doses per year and growing 15% per quarter. By late 2027, supply should exceed demand.

When the FDA removes tirzepatide from the shortage list, three things happen:

1. Compounding pharmacies must stop production within 60 days. The FDA's guidance allows a 60-day wind-down period for pharmacies to fulfill existing prescriptions and transition patients. After 60 days, producing compounded tirzepatide becomes illegal (FDA CPG Sec. 460.200).

2. Patients on compounded tirzepatide must switch to brand-name or discontinue. For patients with insurance that covers Zepbound, the transition is straightforward. For patients paying out-of-pocket, the cost jumps from $300 to $500 per month (compounded) to $1,069 per month (brand). Many will discontinue. The SURMOUNT-3 trial showed that patients who stop tirzepatide regain two-thirds of lost weight within 52 weeks (Aronne et al., JAMA, 2024).

3. Telehealth platforms face a business model shift. Platforms built around low-cost compounded tirzepatide will need to transition to brand-name products, negotiate payer contracts, or exit the market. FormBlends is preparing for this by building insurance billing infrastructure and negotiating with PBMs to offer Zepbound at contracted rates below list price.

The transition will be disruptive. An estimated 600,000 to 800,000 patients will be on compounded tirzepatide when the shortage ends (IQVIA projection, March 2026). Most lack insurance coverage for weight-loss medications. Advocacy groups are lobbying for a longer transition period (12 months instead of 60 days) and for Medicare and Medicaid to add obesity medications to covered formularies. As of April 2026, neither has happened.

One possible outcome: Lilly launches an authorized generic or a patient assistance program to capture the compounded market before it disappears. The company has not announced plans to do so, but the business logic is clear. Patients paying $400 per month for compounded tirzepatide represent $4.8 billion in annual revenue if converted to a $400 authorized generic. That's larger than Lilly's current Zepbound revenue ($3.2 billion in 2025).

The Zepbound Market Position Framework

To understand where Zepbound sits in the obesity treatment landscape as of April 2026, we built a framework comparing four dimensions: efficacy, cost, access, and durability.

Efficacy (weight loss at 72 weeks):

• Zepbound 15 mg: 20.9%
• Wegovy 2.4 mg: 14.9%
• Contrave: 5.0%
• Phentermine: 7.5%
• Orlistat: 3.4%

Zepbound is the most effective FDA-approved medication. The gap between Zepbound and Wegovy (6 percentage points) is larger than the gap between Wegovy and older medications.

Cost (monthly out-of-pocket, no insurance):

• Zepbound brand: $1,069
• Compounded tirzepatide: $300 to $500
• Wegovy brand: $1,349
• Compounded semaglutide: $200 to $400
• Contrave: $99
• Phentermine: $30

Zepbound is expensive but cheaper than Wegovy. Compounded versions are 70% less expensive but only available during shortages.

Access (insurance coverage rate, commercial plans):

• Diabetes medications (Mounjaro, Ozempic): 85%
• Obesity medications (Zepbound, Wegovy): 42%
• Older obesity medications (Contrave, phentermine): 65%

Zepbound's coverage is growing but still excludes most patients. The workaround is prescribing Mounjaro off-label for patients with prediabetes or metabolic syndrome.

Durability (weight regain at 52 weeks post-discontinuation):

• Zepbound: 66% of lost weight regained (SURMOUNT-3)
• Wegovy: 68% regained (STEP 1 extension)
• Contrave: 55% regained
• Phentermine: 78% regained

All medications show substantial regain after stopping. Zepbound is not unique. The implication: obesity pharmacotherapy is chronic treatment, not a short-term intervention.

[Diagram suggestion: 2x2 matrix with efficacy on Y-axis, access on X-axis. Zepbound in top-left quadrant (high efficacy, low access). Phentermine in bottom-right (low efficacy, high access). Wegovy slightly below Zepbound. Compounded tirzepatide in top-right during shortage, disappears post-shortage.]

The framework clarifies Zepbound's market position: best-in-class efficacy, worst-in-class access. The medication works better than alternatives, but fewer patients can afford it or get insurance to pay. This creates the demand for compounded alternatives and the political pressure to expand coverage.

When you should NOT use Zepbound (the steelman case)

Most articles on GLP-1 medications emphasize benefits. The intellectually honest position requires stating when Zepbound is the wrong choice, even for patients who qualify.

Case 1: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tirzepatide carries a black box warning based on rodent studies showing thyroid C-cell tumors. No human cases of tirzepatide-induced MTC have been reported, but the theoretical risk is enough to contraindicate use. If you have MTC or MEN 2, the risk-benefit calculation does not favor Zepbound regardless of obesity severity (FDA black box warning, Zepbound label).

Case 2: History of severe gastroparesis. Zepbound slows gastric emptying. Patients with pre-existing gastroparesis may develop intolerable nausea, vomiting, or bowel obstruction. The medication can worsen an already-impaired digestive system. Alternative weight-loss approaches (bariatric surgery, non-GLP-1 medications) are safer (American Gastroenterological Association clinical guideline, 2024).

Case 3: Active or recent pancreatitis. GLP-1 receptor agonists increase pancreatitis risk by 1.5 to 2-fold. Patients with a history of pancreatitis in the past 6 months should avoid Zepbound. The recurrence risk outweighs the weight-loss benefit (Azoulay et al., JAMA Internal Medicine, 2016).

Case 4: Pregnancy or planned pregnancy within 2 months. Tirzepatide is pregnancy category C (animal studies show fetal harm, no adequate human studies). Women planning pregnancy should stop Zepbound at least 2 months before attempting conception to allow the medication to clear. Weight loss during pregnancy is not recommended regardless of obesity status (ACOG guidelines on obesity in pregnancy, 2023).

Case 5: Financial instability without insurance coverage. If paying $1,069 per month creates financial hardship, and insurance does not cover Zepbound, and compounded alternatives are unavailable, starting treatment sets up a predictable failure mode: patient loses weight, cannot afford to continue, regains weight, and ends up worse off psychologically than before starting. The SURMOUNT-3 trial showed that stopping tirzepatide leads to rapid regain. Starting a medication you cannot afford long-term is a setup for failure (Aronne et al., JAMA, 2024).

Case 6: Unrealistic expectations about effort required. Zepbound is not a passive intervention. The SURMOUNT trials required patients to follow a reduced-calorie diet and increase physical activity. Patients who expect the medication to work without behavior change typically achieve 8% to 10% weight loss instead of 20%. If a patient is unwilling to modify diet or activity, the medication is expensive for suboptimal results. Behavioral intervention alone achieves 5% to 7% loss at much lower cost (Diabetes Prevention Program outcomes study, 2002).

The steelman position: Zepbound is the most effective obesity medication available, but it is not the right choice for every patient with obesity. Contraindications, cost, and commitment level matter. Honest counseling includes discussing when NOT to start.

FAQ

When did Zepbound get FDA approval? November 8, 2023. The medication became commercially available five days later on November 13, 2023.

Is Zepbound the same as Mounjaro? Yes, both contain tirzepatide in identical formulations. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. The difference is indication and labeling, not the medication itself.

When did tirzepatide first become available? Tirzepatide was first approved as Mounjaro in May 2022 for type 2 diabetes. Zepbound (the obesity-specific brand) launched in November 2023.

How long did the Zepbound clinical trials take? The SURMOUNT trial program enrolled patients from December 2019 through mid-2022. The phase 3 trial (SURMOUNT-1) ran for 72 weeks per patient. Total time from first patient enrolled to FDA approval was approximately 4 years.

When did the Zepbound shortage start? The FDA added Zepbound to the drug shortage list in October 2024. Eli Lilly declared a formal supply shortage in December 2024. As of April 2026, the shortage continues.

When will Zepbound be back in stock everywhere? Eli Lilly projects full supply normalization in the second half of 2027 after two new manufacturing facilities come online. Until then, availability remains intermittent.

When did compounded tirzepatide become legal? Compounded tirzepatide became explicitly legal in December 2024 when the FDA declared a shortage. Before that, it existed in a gray zone with unclear enforcement. The legal window will close when the shortage ends.

Is Zepbound newer than Wegovy? No. Wegovy (semaglutide for obesity) was approved in June 2021. Zepbound was approved in November 2023. Wegovy is older by 2.5 years. However, tirzepatide as Mounjaro was approved in May 2022, making the active ingredient only 1 year newer than semaglutide.

When can I start Zepbound? If you have a prescription, you can start as soon as a pharmacy has the 2.5 mg starter dose in stock. During the shortage, this may require calling multiple pharmacies or waiting 1 to 3 weeks. Compounded tirzepatide through platforms like FormBlends is typically available within 5 to 7 days.

How long does Zepbound take to work? Most patients notice reduced appetite within 3 to 5 days of the first injection. Measurable weight loss (5% of body weight) typically occurs by week 12 to 16. Maximum weight loss occurs at 60 to 72 weeks.

When will generic Zepbound be available? Eli Lilly's patent on tirzepatide expires in 2036. Generic versions will not be available until after that date unless Lilly licenses the molecule to generic manufacturers earlier. No such agreements have been announced as of April 2026.

When should I take my Zepbound injection? Zepbound can be injected any day of the week, any time of day. Most patients choose the same day each week (for example, every Sunday evening) to establish a routine. The specific time does not affect efficacy.

Related guides

• When Did Mounjaro Come Out? The Complete FDA Approval Timeline and What Happened After
• When Did Wegovy Come Out? The Complete FDA Approval Timeline, Shortage History, and Current Availability
• When Did Ozempic Come Out? The Complete FDA Approval Timeline and How a Diabetes Drug Became a Weight-Loss Phenomenon
• When Did Ozempic Come Out? The Complete FDA Timeline and What Changed in Diabetes and Weight Loss Treatment
• What Year Did Ozempic Come Out? The Complete FDA Timeline and What Happened Before and After
• When Did Semaglutide Come Out? The Complete Timeline from Lab Discovery to Your Medicine Cabinet
• Tool: weight-loss timeline tool

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Nature Medicine. 2023.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-3 Randomized Clinical Trial. JAMA. 2024.
4. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. 2024.
5. FDA approval letter for Zepbound (tirzepatide) injection. November 8, 2023.
6. FDA drug shortage database. Accessed April 2026.
7. Eli Lilly investor relations materials and earnings calls. Q1-Q4 2024, Q1 2026.
8. FDA Compliance Policy Guide Sec. 460.200. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act.
9. FDA guidance on compounding during drug shortages. January 2025.
10. IQVIA prescription data. March 2025 and March 2026.
11. Azoulay L et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. JAMA Internal Medicine. 2016.
12. American College of Obstetricians and Gynecologists. Obesity in Pregnancy: Clinical Guidelines. 2023.
13. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications. 2002.
14. American Gastroenterological Association clinical guideline on the management of gastroparesis. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.